U.S. stocks recoiled from record levels after investors altered their concentration to a batch of weaker-than-predictable economic reports on Thursday.

The S&P 500 SPX, -0.14% move stealthily lower with almost all of its 10 main sectors in negative territory. Energy stocks were selling off in the wake of a drop in oil prices and weighed on the index. The Dow Jones Industrial Average DJIA, -0.07% recoiled from the record level it reached on Wednesday. More than half of its 30 elements were trading lower, with Chevron Corp and Exxon Mobil leading the losses.

The Nasdaq Composite COMP, +0.17% failed to hold on to earlier modest gains and moved lower.

Insights about some real gainers from healthcare segment in the current trading session, are depicted underneath:

Atossa Genetics, Inc. (NASDAQ:ATOS)’s shares skyrocketed 48.12% and is now trading at $2.37, soon after a healthcare company that focuses on the development of a suite of laboratory services, medical devices, and therapeutics for breast cancer, declared that Henry Schein Medical, the U.S. Medical business of Henry Schein, Inc. (NASDAQ: HSIC), will offer its customers the FullCYTE Breast Aspirator. The Atossa FullCYTE Breast Aspirator is used by OB/GYNs, primary care physicians and women’s clinics to collect fluid from breasts for subsequent cytological evaluation.

Dr. Steven C. Quay, Chairman, President & CEO of Atossa Genetics, commented, “Working with Henry Schein is an important step forward in making the FullCYTE Breast Aspirator accessible nationwide. Henry Schein is an industry leader and its multi-channel sales organization allows for expanded reach into multiple market segments within health care for our device. We are thrilled to work with a company such as Henry Schein and believe our arrangement will contribute positively to our forthcoming nationwide launch.”

Atossa Genetics, Inc. (NASDAQ:ATOS), is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its partner, The National Reference Laboratory for Breast Health, Inc.

Shares of Cyberonics Inc. (NASDAQ:CYBX), jumped nearly 24.80% and is now trading at $75.34, hitting new 52-week high of $76.48, soon after the news release that a medical device company with core expertise in neuromodulation, declared results for the quarter ended January 23, 2015.

Quarterly highlights:

Operating results for the third quarter of fiscal 2015 contrast to the third quarter of fiscal 2014 and other achievements comprise:

• Worldwide net sales of $72.1 million, an raise of 9% on an adjusted basis;
• S. net sales reached $57.6 million, an raise of 9%, with units increasing by 6%;
• Adjusted for the single country order, international sales raised by 18% on a constant currency basis, with units increasing by 18%2;
• Revenue from operations of $23.7 million, an raise of 12%;
• Adjusted non-GAAP net revenue of $15.7 million, an raise of 13%;
• Adjusted non-GAAP revenue per diluted share of $0.59 contrast with revenue per diluted share of $0.51, an raise of 16%;
• Raised adoption of AspireSR® generator; and
• CE Mark approval of the VITARIA generator, which provides Autonomic Regulation Therapy (“ART”) for chronic heart failure.

“Our strong sales results for the third quarter of fiscal 2015 reflect improvement in our U.S. proceeds and one of our best ever international quarters,” commented Dan Moore, President and Chief Executive Officer. “We achieved record sales for our fiscal third quarter in our U.S. business.

Cyberonics purchased 277,000 shares on the open market in the third quarter of fiscal 2015, and as of quarter end, at January 23, 2015.

Cyberonics Inc. (NASDAQ:CYBX), is a medical device company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of medically refractory epilepsy and treatment-resistant depression.

Amarin Corporation plc (NASDAQ:AMRN), surged 14.75% and is now trading at $1.60, soon after a biopharmaceutical company, and Eddingpharm, two pharmaceutical companies focused on the development and commercialization of innovative therapeutics, declared an exclusive contract for Eddingpharm to develop and commercialize Vascepa® (icosapent ethyl) in the territories of the Mainland China, the Hong Kong and Macao Special Administrative Regions and Taiwan for uses that are presently commercialized and under development by Amarin in the United States based on the MARINE, ANCHOR and ongoing REDUCE-IT clinical trials of Vascepa.

Under the contract, Eddingpharm will be responsible for development and commercialization activities in the territory and associated expenses. Amarin will provide development assistance and be responsible for supplying finished, and later bulk, product. Terms of the contract comprise up-front and milestone payments to Amarin of up to $169.0 million, counting a non-refundable $15.0 million up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154.0 million. Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens. Amarin will supply product to Eddingpharm under negotiated supply terms.

“Vascepa has the potential to occupy a leading position in the substantial worldwide market for prescription omega-3 products,” commented John F. Thero, President and Chief Executive Officer of Amarin. “Our contract with Eddingpharm reflects the culmination of a competitive process and represents a noteworthystep toward commercializing Vascepa in a major market outside the United States. We are very happy to be collaborating with Eddingpharm. We believe that their team is well suited to successfully introduce Vascepa in China. Eddingpharm has established development and regulatory capabilities and an impressive commercial organization that has launched many innovative products in China. Eddingpharm’s successful track record of long-term alliances with leading global pharmaceutical companies gives us confidence in Vascepa’s success in China. The contract also validates the Vascepa and REDUCE-IT investment hypothesis and marks our start at licensing the ex-US rights to Vascepa to leading commercialization partners around the world.”

Amarin Corporation plc (NASDAQ:AMRN), is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin’s clinical program comprises commitment to an ongoing outcomes study.

Shares of the Endologix Inc. (NASDAQ:ELGX), gained 11.83% & is now trading at $16.35, following the news release that developer and marketer of innovative treatments for aortic disorders, declared financial results for the three and twelve months ended December 31, 2014.

Endologix stated a net loss for the fourth quarter of 2014 of $14.8 million, or $(0.22) per share, contrast with $3.4 million net loss, or $(0.05) per share, for the fourth quarter of 2013. The fourth quarter 2014 net loss comprises Nellix contingent consideration, interest expense, foreign currency loss and business development expenses of $7.6 million, while the fourth quarter 2013 net loss comprises other expenses of $2.7 million, primarily Nellix contingent consideration. Endologix stated Adjusted Net Loss for the fourth quarter of 2014 of $7.2 million or $(0.11) per share, contrast with an Adjusted Net Loss for the fourth quarter of 2013 of $0.8 million, or $(0.01) per share.

For the year ended December 31, 2014, Endologix stated a net loss of $32.4 million, or $(0.50) per share, contrast to a net loss of $16.1 million, or $(0.26) per share, for the year ended December 31, 2013. Endologix stated an Adjusted Net Loss (non-GAAP and defined below) for the year ended December 31, 2014 of $24.8 million or $(0.38) per share, contrast with an Adjusted Net Loss (non-GAAP and defined below) for the year ended December 31, 2013 of $7.1 million, or $(0.11) per share.

Total cash, cash equivalents and marketable securities were $86.7 million as of December 31, 2014, contrast to $126.5 million as of December 31, 2013.

Endologix Inc. (NASDAQ:ELGX), develops and manufactures minimally invasive treatments for aortic disorders. Endologix’s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement.